Loading...
XHKG9939
Market cap54mUSD
Dec 27, Last price  
0.97HKD
1D
0.00%
1Q
-11.01%
IPO
-95.31%
Name

Kintor Pharmaceutical Ltd

Chart & Performance

D1W1MN
XHKG:9939 chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
355.69%
Rev. gr., 5y
%
Revenues
0k
001,458,367489,9216980034,23100
Net income
-1.06b
L+11.15%
-8,345,652-11,441,126-54,225,918-46,216,636-108,484-232,577,000-508,301,000-842,095-954,369,000-1,060,820,000
CFO
-388m
L+40,220.10%
0000-114,868-228,042-380,882-1,051,363-961,260-387,581,000
Earnings
Jun 20, 2025

Profile

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer and basal-cell carcinoma. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
IPO date
May 22, 2020
Employees
290
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
34
 
Cost of revenue
1,076,483
979,332
885
Unusual Expense (Income)
NOPBT
(1,076,483)
(979,332)
(850)
NOPBT Margin
Operating Taxes
8,041
1,085
(230)
Tax Rate
NOPAT
(1,084,524)
(980,417)
(620)
Net income
(1,060,820)
11.15%
(954,369)
113,232.70%
(842)
-99.83%
Dividends
Dividend yield
Proceeds from repurchase of equity
755
698,763
951,972
BB yield
Debt
Debt current
118,230
103,335
9,469
Long-term debt
142,510
10,064
4,980
Deferred revenue
19,657
19,952
4,009
Other long-term liabilities
(58,770)
(42,827)
Net debt
(202,756)
112,504
13,393
Cash flow
Cash from operating activities
(387,581)
(961)
(1,051)
CAPEX
(3)
(27)
(76)
Cash from investing activities
3,274
67
92
Cash from financing activities
(33,463)
816
857
FCF
(1,171,307)
(1,074,367)
75,757
Balance
Cash
455,499
877
1,057
Long term investments
7,997
18
Excess cash
463,496
895
1,055
Stockholders' equity
3,845,709
(2,609)
(1,704)
Invested Capital
268,193
2,120,045
2,038,027
ROIC
ROCE
EV
Common stock shares outstanding
429,069
376,566
356
Price
Market cap
EV
EBITDA
(1,057,507)
(979,314)
(840)
EV/EBITDA
Interest
2,494
Interest/NOPBT